Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Infections Post Transplant

Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study

Bone Marrow Transplantation volume 28, pages 759–763 (2001)Cite this article

Abstract

Infections with the paramyxoviruses, respiratory syncytial virus (RSV) and parainfluenza virus (PIV) can result in serious morbidity and mortality after haemopoietic stem cell transplant (HSCT). Once pneumonia develops, the outcome of these infections is often poor despite anti-viral therapy. Aerosolised ribavirin has been evaluated as pre-emptive therapy for post-transplant RSV infections with some success. Due to the financial and logistic burden involved with the use of aerosolised ribavirin, we explored the efficacy and toxicity of oral ribavirin for pre-emptive therapy of post-transplant RSV and PIV infections in a dose escalating schedule (15–60 mg/kg/day). Five episodes each of RSV and PIV were treated in seven patients. Five patients were receiving treatment for GVHD and two acquired the infection in the pre-engraftment period. All the episodes of RSV infection improved with oral ribavirin with dose escalation to 30–45 mg/kg in three of them. On the other hand, only two of the five PIV infections improved with oral ribavirin. Of the three non-responders, two infections were acquired in the pre-engraftment period with one death from PIV pneumonia. Reversible anaemia was the only side-effect noted in patients treated for over 2 weeks. Thus, the use of oral ribavirin was well tolerated in the post-transplant period with no untoward toxicities. There was a trend towards better response in RSV infections, which needs to be further explored in controlled studies. Bone Marrow Transplantation (2001) 28, 759–763.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Ljungman P . Respiratory virus infections in bone marrow transplant recipients: the European perspective Am J Med 1997 102: 44–47

    Article  CAS  Google Scholar 

  2. Bowden RA . Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience Am J Med 1997 102: 27–30

    Article  CAS  Google Scholar 

  3. Whimbey E . Champlin RE, Couch RB et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients Clin Infect Dis 1996 22: 778–782

    Article  CAS  Google Scholar 

  4. Whimbey E, Englund JA, Couch RB . Community respiratory virus infections in immunocompromised patients with cancer Am J Med 1997 102: 10–18

    Article  CAS  Google Scholar 

  5. Wendt CH, Weisdorf DJ, Jordan MC et al. Parainfluenza virus respiratory infection after bone marrow transplantation New Engl J Med 1992 326: 921–926

    Article  CAS  Google Scholar 

  6. Ghosh S, Champlin RE, Englund J et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirinand intravenous immunoglobulin Bone Marrow Transplant 2000 25: 751–755

    Article  CAS  Google Scholar 

  7. Adams R, Christenson J, Petersen F, Beatty P . Pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV Bone Marrow Transplant 1999 24: 661–664

    Article  CAS  Google Scholar 

  8. McCarthy AJ, Kingman HM, Kelly C et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation Bone Marrow Transplant 1999 24: 1315–1322

    Article  CAS  Google Scholar 

  9. Chakrabarti S, Collingham KE, Holder K et al. Parainfluenza virus type 3 infections in haematopoetic stem cell transplant recipients: response to ribavirin therapy Clin Infect Dis 2000 31: 1516–1518

    Article  CAS  Google Scholar 

  10. Aslan T, Fassas AB, Desikan R et al. Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy Bone Marrow Transplant 1999 24: 505–509

    Article  CAS  Google Scholar 

  11. Sparrelid E, Ljungman P, Ekelof-Andstrom E et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections Bone Marrow Transplant 1997 19: 905–908

    Article  CAS  Google Scholar 

  12. Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood 2000 96: 2419–2425

    CAS  PubMed  Google Scholar 

  13. Chakrabarti S, Collingham KE, Holder K et al. Respiratory virus infections in adult T cell depleted transplant recipients: role of cellular immunity Transplantation (in press)

  14. Glue P . The clinical pharmacology of ribavirin Semin Liver Dis 1999 19: 17–24

    CAS  PubMed  Google Scholar 

  15. Tam RC, Pai B, Bard J et al. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile J Hepatol 1999 30: 376–382

    Article  CAS  Google Scholar 

  16. Alwan WH, Record FM, Openshaw PJ . CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells Clin Exp Immunol 1992 88: 527–536

    Article  CAS  Google Scholar 

  17. Varga SM, Wissinger EL, Braciale TJ . The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4(+) T cell responses J Immunol 2000 165: 6487–6495

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Birmingham Heartlands Hospital, Birmingham, UK

    S Chakrabarti, K Holder, CD Fegan & DW Milligan

  2. Public Health Laboratory, Birmingham Heartlands Hospital, Birmingham, UK

    KE Collingham & H Osman

Authors
  1. S Chakrabarti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. KE Collingham
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Holder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. CD Fegan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Osman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. DW Milligan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chakrabarti, S., Collingham, K., Holder, K. et al. Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant 28, 759–763 (2001). https://doi.org/10.1038/sj.bmt.1703216

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703216

Keywords

This article is cited by

Search

Advanced search

Quick links